116.63
Axsome Therapeutics Inc stock is traded at $116.63, with a volume of 656.38K.
It is down -1.60% in the last 24 hours and down -8.55% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$118.53
Open:
$115.62
24h Volume:
656.38K
Relative Volume:
0.74
Market Cap:
$5.71B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-17.86
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
-9.71%
1M Performance:
-8.55%
6M Performance:
+29.78%
1Y Performance:
+46.15%
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Compare AXSM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AXSM
Axsome Therapeutics Inc
|
116.63 | 5.71B | 338.46M | -310.96M | -132.82M | -6.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-11-25 | Initiated | Deutsche Bank | Buy |
Dec-31-24 | Reiterated | Mizuho | Outperform |
Sep-03-24 | Initiated | Wells Fargo | Overweight |
Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
Jul-22-24 | Initiated | Needham | Buy |
Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Mar-19-24 | Initiated | Robert W. Baird | Outperform |
Feb-06-24 | Initiated | UBS | Buy |
Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
Dec-13-23 | Initiated | Citigroup | Buy |
Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-05-23 | Initiated | Piper Sandler | Neutral |
Nov-01-22 | Initiated | Loop Capital | Buy |
Sep-07-22 | Resumed | Mizuho | Buy |
Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-10-21 | Initiated | Berenberg | Buy |
Jan-08-21 | Initiated | Jefferies | Buy |
Dec-16-20 | Initiated | Mizuho | Buy |
Sep-29-20 | Initiated | BofA Securities | Underperform |
Sep-10-20 | Initiated | Morgan Stanley | Overweight |
Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
Apr-14-20 | Initiated | Cowen | Outperform |
Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
Dec-16-19 | Reiterated | Guggenheim | Buy |
Oct-16-19 | Initiated | Guggenheim | Buy |
Sep-18-19 | Initiated | William Blair | Outperform |
May-28-19 | Initiated | SunTrust | Buy |
May-23-19 | Reiterated | H.C. Wainwright | Buy |
Apr-08-19 | Initiated | SVB Leerink | Outperform |
Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
Oct-03-16 | Resumed | Brean Capital | Buy |
Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $216.00 - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by Analysts - MarketBeat
Loomis Sayles & Co. L P Sells 8,475 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4.9%Here's Why - MarketBeat
Fox Run Management L.L.C. Makes New $518,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
(AXSM) Proactive Strategies - Stock Traders Daily
Cibc World Markets Corp Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome succeeds in late-stage trial for ADHD therapy - MSN
Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views - Benzinga
Medical Properties Trust : Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint - MarketScreener
Bayer gains cancer drug from China’s Puhe; Axsome gets mixed ADHD data - BioPharma Dive
AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Mizuho Securities Adjusts Axsome Therapeutics Price Target to $216 From $212, Maintains Outperform Rating - Marketscreener.com
Axsome’s Sunosi succeeds in Phase III ADHD trial - Yahoo Finance
13,460 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by HighTower Advisors LLC - MarketBeat
Intech Investment Management LLC Acquires 5,087 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report - biocentury.com
Why Pharma and Biotech Stocks Got Thrashed on Tuesday - The Motley Fool
Axsome’s Scores In ADHD, But Differentiation In Generic-Heavy Market Unclear - insights.citeline.com
Axsome reports Phase 3 win for Sunosi in adults with ADHD, with a high-dose caveat - Endpoints News
Axsome Therapeutics’ Promising Phase III FOCUS Trial Results Boost Buy Rating - TipRanks
Axsome shares fall after ADHD trial results By Investing.com - Investing.com UK
Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal - Benzinga
Axsome stock rises on trial win for ADHD drug (AXSM:NASDAQ) - Seeking Alpha
Axsome Therapeutics' ADHD Trial Achieves Primary, Key Secondary Endpoints - Nasdaq
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint - MarketScreener
New ADHD treatment shows promise in phase 3 trial - Investing.com
Axsome Therapeutics' ADHD drug meets main goal in late-stage study - TradingView
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention - Bluefield Daily Telegraph
Major Breakthrough: Axsome's ADHD Drug Shows 45% Symptom Reduction in Phase 3 Trial - Stock Titan
Strong Growth and Positive Outlook for Axsome Therapeutics’ Auvelity Drives Buy Rating - TipRanks
Royce & Associates LP Acquires 14,500 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Privium Fund Management B.V. Has $5.27 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Raymond James Financial Inc. Purchases Shares of 174,586 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome: The Alzheimer’s Agitation Program For AXS-05 (NASDAQ:AXSM) - Seeking Alpha
Charles Schwab Investment Management Inc. Grows Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Connor Clark & Lunn Investment Management Ltd. Takes $6.22 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Great Lakes Advisors LLC Sells 3,220 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
How To Trade (AXSM) - Stock Traders Daily
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):